Version June 2024
| Class | Agent(s) | Comment |
| Primary uricosurics | Probenecid, sulfinpyrazone*, benzbromarone*, lesinurad | |
| Urate oxidase (uricolytics) | Pegloticase, rasburicase | Converts uric acid to allantoin (inactive water soluble metabolite). |
| Drugs with secondary uricosuric effect | ||
| Angiotensin-converting enzyme (ACE) inhibitors | Enalapril, captopril | Other ACE inhibitors do not seem to increase uric acid excretion. |
| Angiotensin II receptor blocker (ARB) | Losartan | Only ARB that significantly lowers serum uric acid. May counteract uric acid increase due to thiazide or cyclosporine. |
| Calcium channel blockers, dihydropyridine | Amlodipine, felodipine, nitrendipine, nicardipine | Shown to decrease serum uric acid in patients taking cyclosporine following renal graft. |
| Fibric acid derivative | Fenofibrate (micronized) | Significant uricosuric effect; data are lacking on effect of other fibrates. |
| Statins | Atorvastatin | Modest effect; studies of other statins demonstrated inconsistent or no effect. |
| Anti-infectives | Trimethoprim-sulfamethoxazole, ampicillin, rifampin, isoniazid | |
| Hormone replacement therapy | Estrogen | |
| Salicylates (high doses), aspirin, selected NSAIDs | Diflunisal, aspirin (high dose >3 g/day and low dose 75 mg/day), sulindac, phenylbutazone* | Moderate doses of aspirin can cause uric acid retention. |
| Sodium-glucose cotransporter 2 (SGLT2) inhibitors | Canagliflozin, dapagliflozin, empagliflozin, ertugliflozin | Effect likely mediated by the inhibitory effect of glycosuria on urate reabsorption. |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
